HungaryHungary

Bipolar drug – conflicting result

16.09.2010

Budapest – Hungary’s largest drugmaker Gedeon Richter Ltd. and US partner Forest Laboratory said that a Phase II clinical trial of their orally active drug cariprazine (RGH-188) for bipolar depression produced no “statistically significant” result compared with placebo treatment. The companies tested two dosages of their once-daily D3/D2 dopamine receptor partial agonist/antagonist in 234 adult patients with bipolar I or II depression without psychotic features in a two-arm study with a low dose (0.25-0.75 mg/day) and high-dose group (1.5- 3.0 mg/day).
While no effect was observed after 8 weeks of treatment in the low-dose group, the development partners announced at the end of August that “there was evidence of a clinically relevant treatment effect in the high-dose arm.” Gedeon Richter and Forest Laboratories are now expected to conduct an additional Phase II dose-response trial to examine a wider range of doses.
Cariprazine is currently being tested in several Phase III trials for schizo­phrenia and bipolar mania. The drug acts as a D3/D2 antagonist/partial agonist, depending on actual dopaminergic tone, and preferentially binds to D3 receptors.

HungaryHungary

05.03.2012

It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner...

HungaryHungary

09.08.2011

Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Bio­tech sro to provide the Hungarian firm’s drug transporter assays to its customers in the bio­pharmaceutical...

HungaryHungary

09.08.2011

Budapest/Kraków – In July, illegally planted genetically modified crops made headlines in Hungary, where GMO acreage is banned. Up to 0.1% GMO maize products from Monsanto and Pioneer were discovered at four sites (near...

HungaryHungary

04.04.2011

Budapest – Hungarian vaccine developer Genetic Immunity Kft. (GI) has secured a cash injection of US$25m by signing an agreement with the Budapest-based technology commercialisation company Power of the Dream Ventures, Inc. The...

HungaryHungary

06.02.2011

Budapest/Tokyo – Hungary’s largest drugmaker Gedeon Richter Nyrt. has secured access to the Japanese market for its biosimilar pipeline. In mid-December, Richter CEO Erik Bogsch announced his company had signed a long-term...

HungaryHungary

03.11.2010

Budapest – Richter Group has bagged Swiss gynecology and infertility specialist Preg­Lem Holding SA in a 100 % equity stake worth up to EUR 359m. Hungary’s largest drugmaker expects PregLem’s lead candi­date Esmya as...

HungaryHungary

01.07.2010

Budapest – New results from researchers at the Department of Pathology and Experimental Cancer Research in Budapest suggest that expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) on the surface of chronic...

HungaryHungary

01.02.2010

Budapest – ChemAxon, a specialist for chemical informatics software for the life sciences industry, has entered into an agreement with Pfizer. Under the terms of the agreement, Chemaxon will provide its Markush searching and...

HungaryHungary

30.12.2009

Budapest/Zug/Edinburgh – Swiss/Hungarian antibody specialist ImmunoGenes has inked a collaboration and license agreement with the Scottish Roslin Institute to develop specialised sheep that use ImmunoGenes’ proprietary technology...

Displaying results 1 to 10 out of 89

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-hungary/article/bipolar-drug-conflicting-result.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR32.3%
  • ADDEX3.44 CHF7.8%
  • HBM86.00 CHF4.4%

FLOP

  • PAION2.19 EUR-32.8%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-25.0%

TOP

  • SANTHERA82.00 CHF2184.1%
  • CO.DON2.82 EUR200.0%
  • PAION2.19 EUR157.6%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 22.10.2014


Current issue

All issues

Product of the week

Products